BRAF and neoplasm: Regorafenib, cabozantinib and ramurciumab were initially evaluated in patients previously treated with sorafenib (Table 1).[36], [37], [38] Regorafenib blocks the activity of multiple protein kinases involved in angiogenesis, proliferation, tumour microenvironment, and metastasis, including VEGFR1-3, TIE2, KIT, RET, RAF-1, BRAF, PDGFR, and FGFR.39